About the Centre

The MRC-funded Centre for Drug Safety Science was established at the University of Liverpool in 2009 to bring together a critical mass of knowledge and technologies in order to advance our understanding of Adverse Drug Reactions (ADRs).  The Centre received renewed funding for a further five years in 2014.


Our Mission

To use the critical mass and knowledge in drug safety science that we have now accrued within the Centre to undertake leading edge science, and train the next generation of drug safety scientists, to understand the fundamental mechanisms of clinically important, and currently relevant, adverse drug reactions in order to develop strategies to improve the benefit-risk ratio of current and new medicines, for the benefit of patients, industry and regulators. 


Our Aims

  • To provide new knowledge that will inform the future design and development of medicines.
  • To evaluate the potential contribution of new technologies to the pre-clinical toxicological assessment of drugs and integration of the results with the findings from clinical studies, with particular reference to the development of novel biomarkers of drug safety.
  • To act as a catalyst for future research into areas of high importance for ADRs, which are not currently adequately addressed within academia.
  • To provide an environment that will enable the development of cross-disciplinary research programmes into the fundamental mechanisms of ADRs.
  • To provide an environment for collaboration between scientists from academia, research institutes, government and industry.
  • To provide an environment that will foster the training of the next generation of drug safety scientists. These scientists will be either clinical or non-clinical with various backgrounds in academia, industry and drug regulation.
  • To enhance the career development of drug safety scientists by providing them with the breadth and depth of intellectual and practical training that no one organisation can provide.
  • To provide impartial advice to NHS, Industry and Regulatory Authorities.
  • To inform the public about the fundamental issues associated with drug safety and to develop a culture of understanding of the collective risks and benefits for society as a whole for the use of medicines in the treatment of disease.